Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6
Open accessPublished version of a preprint
The DOI matches its Crossref record; 43 of the 45 references it cites were found in a registry or an index.
Abstract
Dysregulation of the p16-cyclin D1-CDK4/6-Rb pathway occurs frequently in melanoma; however, the therapeutic efficacy of CDK4/6 inhibition remains to be critically evaluated. We demonstrate that CDK4/6 inhibition inhibits melanoma progression through induction of senescence. Palbociclib, a specific CDK4/6 inhibitor, rapidly induces cell cycle arrest within 24 hours and continued exposure for 8 days or longer induces senescence. The induction of senescence correlates with inhibition of mTOR and more specifically mTORC1 signaling. Vemurafenib, a specific BRAF(V600E) inhibitor, has significant clinical efficacy in BRAF(V600E)-positive melanomas, but its impact is hampered by a rapid acquisition of resistance. Strikingly, we found that vemurafenib-resistant tumors remain sensitive to palbociclib, suggesting that initial treatment with vemurafenib followed by palbociclib with or without mTOR inhibitors might provide an avenue to overcome recurrence of vemurafenib-resistant metastatic disease. Taken together, these results support palbociclib as a promising therapeutic for treatment of melanoma. Cancer Res; 76(10); 2990-3002. ©2016 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In contrast to this however, mTOR inhibition is crucial to reach oncogene induced senescence in mouse models of melanoma, and mTOR inhibition can cooperate with CDK4/6 inhibition to drive senescence in melanoma cell lines (Damsky et al., 2015; Yoshida et al., 2016).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Yoshida et al., 2016
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In addition, doxorubicin-induced senescence in H9c2 myocardial cells results in increased expression of 4-HNE and GPX4, decreased SIRT1 expression, and heightened levels of pro-inflammatory cytokines (IL-6, IL-17, and TNF-α), while the anti-inflammatory cytokine IL-4 is reduced.291–293”
From Inflammation and aging: signaling pathways and intervention therapies (2023) · cites this paper as [293]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509 · cited 1×
“Although mTORC1 complex is a master regulator of cell proliferation and metabolism through phosphorylation of S6K and 4EBP1, mTORC2 has a more direct impact on cell proliferation, survival, and metabolism through the regulation of AKT (34).”
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · cited 1×
“Initial treatment of vemurafenib results in tumor shrinkage lasting 3 to 6 months in clinical trials; unfortunately however, tumors relapse due to the acquired resistance to vemurafenib, and overall survival is only extended several months (15).”
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
Kim, D.-H., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2002) · Cell · doi:10.1016/s0092-8674(02)00808-5 · Cited by 2,986 · cited 1×
“mTOR is a serine/threonine kinase that serves as the common catalytic component of two distinct complexes commonly referred to as mTORC1 and mTORC2 (32-34).”
Cellular senescence: from physiology to pathology
Muñoz-Espín, D., & Serrano, M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3823 · Cited by 2,818 · cited 1×
“Senescence, initially identified by Hayflick and Moorhead, is induced by a number of biological stresses such as DNA damage accumulation, acute oncogene activation, reactive oxygen species (ROS), and expression of INK4A/ARF locus in over passaged primary cells in a p53 dependent or independent manner (16).”
Sarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665 · cited 1×
“mTOR is a serine/threonine kinase that serves as the common catalytic component of two distinct complexes commonly referred to as mTORC1 and mTORC2 (32-34).”
BRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160 · cited 1×
“However Braf alone elicits senescence (1, 2).”
Palbociclib in hormone-receptor-positive advanced breast cancer
Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505270 · Cited by 1,590
Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398 · cited 2×
“Palbociclib is being tested in more than seventeen clinical trials for malignancies such as mantle cell lymphoma, breast cancer, and colorectal cancer (18-21).”
Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236 · cited 4×
“Palbociclib is being tested in more than seventeen clinical trials for malignancies such as mantle cell lymphoma, breast cancer, and colorectal cancer (18-21).”
Influential
Cited by
Inflammation and aging: signaling pathways and intervention therapies
Li, X., Li, C., Zhang, W., Wang, Y., Qian, P., & Huang, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01502-8 · Cited by 1,443
Exploiting senescence for the treatment of cancer
Wang, L., Lankhorst, L., & Bernards, R. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00450-9 · Cited by 867
Unmasking senescence: context-dependent effects of SASP in cancer
Faget, D. V., Ren, Q., & Stewart, S. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0156-2 · Cited by 863
Targeting CDK4 and CDK6 in cancer
Goel, S., Bergholz, J. S., & Zhao, J. J. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00456-3 · Cited by 531
CDK4 and CDK6 kinases: From basic science to cancer therapy
Fassl, A., Geng, Y., & Sicinski, P. (2022) · Science · doi:10.1126/science.abc1495 · Cited by 464
“Decreased mTOR signaling after long-term CDK4/6 inhibition was shown to be essential for the induction of senescence in melanoma cells, and activation of mTORC1 overrode palbociclib-induced senescence (72).”
Metadata
- Authors
- Yoshida, A., Lee, E. K., & Diehl, J. A.
- Affiliations
- Medical University of South Carolina (US)
- University of Michigan (US)
- Corresponding author
- Diehl, J. Alan
- Venue
- Cancer Research
- Published
- 2016-05-12
- Volume
- 76
- Issue
- 10
- Pages
- 2990-3002
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- PMC
- PMC4873417
- OpenAlex
- W2300472255
- Cited by
- 153
- References
- 45
- Citations by year
- 2026: 5 · 2025: 10 · 2024: 11 · 2023: 15 · 2022: 23 · 2021: 16 · 2020: 25 · 2019: 13 · 2018: 17 · 2017: 15 · 2016: 3
- FWCI
- 8.32
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P01CA098101, R01CA133154)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Keywords
- melanoma, vemurafenib resistance, CDK4/6 inhibition, palbociclib, senescence, mTORC1 signaling, BRAF V600E mutation, cell cycle arrest, combination therapy, metastatic melanoma
- MeSH terms
- Vemurafenib, Animals, Flow Cytometry, Fluorescent Antibody Technique, Humans, Immunoenzyme Techniques, Indoles, Melanoma, Mutation, Piperazines, Pyridines, RNA, Messenger, Sulfonamides, Tumor Cells, Cultured, Blotting, Western, Gene Expression Regulation, Enzymologic, Gene Expression Regulation, Neoplastic, Mice, SCID, Cellular Senescence, Apoptosis, Drug Resistance, Neoplasm, Reverse Transcriptase Polymerase Chain Reaction, Xenograft Model Antitumor Assays, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Cell Proliferation, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Mice, Real-Time Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6. https://app.cochat.ai/papers/10.1158/0008-5472.can-15-2931
- The paper
- Yoshida, A., Lee, E. K., & Diehl, J. A. (2016). Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6. Cancer Research. https://doi.org/10.1158/0008-5472.can-15-2931
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.